首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 46 毫秒
1.
目的 观察高强度聚焦超声(HIFU)治疗不能手术的中晚期胰腺癌的2年生存情况.方法 对38例不能手术的中晚期胰腺癌患者进行HIFU治疗,记录术后肿瘤标志物、疼痛评分、生活质量评分的变化和生存情况.结果 HIFU治疗前有疼痛症状的35例患者,治疗后有28例患者疼痛症状有缓解(80.0%).38例患者糖类抗原19-9(CA19-9)和癌胚抗原(CEA)较HIFU治疗前明显降低.影像学检查显示HIFU治疗区呈凝固性坏死表现,随访中肿瘤体积明显缩小.患者的中位生存期延长为(12.9±6.6)个月.结论 HIFU治疗能有效改善不能手术的胰腺癌患者生活质量,延长生存期.  相似文献   

2.
目的探讨MRI增强扫描在脾功能亢进症高强度聚焦超声(HIFU)治疗后疗效评估中的价值。方法回顾性分析15例脾
功能亢进症患者HIFU治疗前后的MRI平扫和增强图像,观察病灶HIFU治疗前后的信号变化和强化特点。结果HIFU治疗
后脾脏靶区在T1WI上无特异性,高、等、低信号区都可代表凝固性坏死;在T2WI上,凝固性坏死表现为低信号;增强扫描示靶区
无强化,病灶范围较T1WI和T2WI广泛。结论T2WI对脾亢HIFU消融脾脏后的凝固性坏死有较高的特异性;动态增强扫描可
以敏感地反映HIFU消融靶区的血供情况及其强化特征。MRI是临床上HIFU治疗脾亢后随访监测病灶变化无创、有效的手
段,能准确反应其组织学变化。
  相似文献   

3.
目的探讨高强聚焦超声(HIFU)热疗对胰腺癌患者的疗效、安全性及肿瘤标志物CA19-9和CEA的影响。方法观察41例自愿接受HIFU治疗的胰腺癌患者的临床受益反应(CBR),用化学免疫分析法检测CA19-9和CEA浓度,进行疗效评价。结果41例胰腺癌患者中3例完全缓解(CR),15例部分缓解(PR),11例稳定(SD),27例临床受益,CBR率达65.8%。治疗后22例(54%)患者疼痛症状明显缓解;14例(34%)肿瘤明显缩小;18例(44%)无变化;9例(22%)有不同程度的增大;23例CA19-9、CEA的浓度下降;中位生存期6.5个月;所有患者均未见明显不良反应。结论高强度聚焦超声热疗能控制肿瘤进展、改善生活质量、对肿瘤标志物CA19-9、CEA有明显下调作用,无明显不良反应,作为一种新的安全有效的局部治疗方法可用于胰腺癌的治疗。  相似文献   

4.
徐林刚  朱秀益  邱勇钢  陈萍 《浙江医学》2023,45(13):1427-1430
目的 探讨增强MRI检查在高强度聚焦超声子宫肌瘤消融术(HIFU)治疗子宫肌瘤疗效评估中的应用价值。方法选择2019年6月至2021年8月绍兴第二医院行HIFU治疗的子宫肌瘤患者110例,共160个肌瘤,所有患者在HIFU治疗前、治疗后1d、治疗后6个月行增强MRI检查。分析MRI检查结果中肌瘤强化情况以及体积,计算术后1d消融率及术后6个月肌瘤的体积缩小率。结果HIFU治疗前,增强MRI检查结果显示瘤灶处呈高信号,160例子宫肌瘤肿瘤体积为0.50~459.41 (126.43±32.75)cm3。T1WI呈低强化肌瘤的消融率明显高于等强化、混杂强化、高强化肌瘤(均P<0.05)。HIFU治疗后6个月,低强化肌瘤的体积缩小率明显高于等强化、混杂强化、高强化肌瘤(均P<0.05)。结论增强MRI检查结果有助于评估HIFU治疗子宫肌瘤的临床疗效。术前T1WI呈低强化子宫肌瘤采用HIFU治疗消融率最高,且患者治疗后6个月肌瘤体积缩小率最大。  相似文献   

5.
目的探讨高强度超声聚焦(HIFU)对晚期胰腺癌患者治疗的效果和安全性。方法对近期收治的20例晚期胰腺癌患者应用高能超声聚焦刀治疗。通过主要脏器功能测定,超声及CT检查肿瘤体积变化,通过血清标志物CA19-9、CA242等指标的测定观察HIFU的疗效。结果治疗后85%的患者癌性疼痛症状得到了较大缓解;7-21 d影像学检查显示:与治疗前相比,治疗后肿瘤体积缩小的有9例,占45.00%;无明显变化的有8例,占40.00%;增大的有3例,占15.00%。CT增强扫描显示,有6例肿瘤已无明显强化,14例肿瘤有部分区域还有强化,表明有血流存在,肿瘤未完全热毁损,还需再次或多次治疗;CA19-9、CA242等标志物浓度下降;近期内无明显并发症出现。结论HIFU治疗晚期胰腺癌患者可明显缓解症状,改善生活质量,延长生存时间,且治疗相对安全。  相似文献   

6.
我科自2005年引进高能超声聚焦肿瘤治疗机(HIFU)以来,对24例中晚期胰腺癌患者进行了治疗,获得了较好的疗效,现报道如下。1资料和方法1.1一般资料本组24例胰腺癌患者系我院2005年7月至2007年12月所收治,诊断依据为病理确诊或典型的临床症状和体征、肿瘤标志物(CA19-9)明显升高并有典型的CT/MRI影像学表现。其中男16例,女8例,年龄48~80(中位年龄62)岁。肿瘤病灶位于胰头部  相似文献   

7.
漆明刚  邝琰  杨样平 《西部医学》2012,24(4):754-756,762
目的探讨低场MRI在高强度聚焦超声治疗子宫肌瘤的早期疗效价值。方法 29例(35个肌瘤)子宫肌瘤行高强多聚焦超声(HIFU)治疗。分别于治疗前1~7天、治疗后1~3天行核磁共振(MRI)检查,分析治疗前后MRI信号变化。结果子宫肌瘤HIFU治疗术后1~3天,34个病灶主体不同程度T1WI信号增高,外周等低信号,T2WI病灶呈中央低信号内散在斑片状高信号,外周高信号环,与治疗前比较:外周高信号环较前明显增宽,病灶内高信号减少;病灶大小无明显变化。结论 MRI平扫是评价子宫肌瘤HIFU治疗早期疗效的方便、经济、有效方法。  相似文献   

8.
目的探讨清热化湿中药联合高强度聚焦超声(HIFU)治疗晚期胰腺癌的临床疗效。方法 86例晚期胰腺癌患者中有18例进行了2~3次HIFU治疗,其余68例仅接受了1次HIFU治疗,伴肝转移的53例患者中有8例同时进行了肝转移灶的HIFU消融治疗。患者HIFU治疗前后和随访期间均给予清热化湿为主的中药治疗。结果治疗后1个月HIFU辐照病灶完全缓解(CR)0例,部分缓解(PR)8例(9.3%),稳定(SD)64例(74.4%),进展(PD)14例(16.3%)。全组患者中位生存时间6个月,半年和1年生存率分别是52.0%、11.4%。73例治疗前糖类抗原199(CA199)升高的患者,治疗后有12例下降,36例治疗前糖类抗原242(CA242)升高的患者治疗后有15例下降。所有病例治疗后疼痛缓解有效率为70.9%(61/86)。结论清热化湿中药联合HIFU治疗是晚期胰腺癌有效的治疗方法。  相似文献   

9.
高强度聚焦超声治疗肝癌的早期MRI表现   总被引:1,自引:0,他引:1  
①目的 探讨肝癌高强度聚焦超声(HIFU)治疗后的早期MRI表现.②方法 29例经病理或临床诊断肝癌患者在HIFU治疗前、后行腹部轴位T1WI,轴位T2WI,冠状位SPIR,以及Gd-DTPA增强后T1WI轴位、FFE序列冠状位扫描.在MRl图像上观察肿瘤在HIFU治疗前、后的大小及信号改变.③结果 HIFU治疗36个癌灶,其中28个缩小(77.8%),5个增大(13.9%),3个无明显变化(8.3%);在T1WI增强上30个瘤灶(83.3%)出现无信号增强区,12个癌灶无增强区周围见环状强化,7个强化环内见低信号环(T1WI、T2WI、SPIR).无强化区大多在T1WI表现为低或高信号,T2WI表现为低、等或高信号.治疗后在T1WI 19个(52.8%)相对信号强度增加,T2WI 17个(47.2%)相对信号强度减弱(与正常肝组织信号相比).④结论 HIFU治疗后,肝癌瘤灶内可出现多种MRI信号改变,具有一定的特征性.MRI是HIFU治疗效果评估的一种无创而有效的影像学检查方法.  相似文献   

10.
目的探讨高强度超声聚焦刀(HIFU)治疗子宫肌瘤的疗效和MRI对其的评价。方法确诊子宫肌瘤患者40例,共48个病灶,行HIFU消融治疗,治疗前后行MRI平扫及增强扫描认真比较肿瘤的信号变化、血供情况及体积。结果 HIFU治疗1个月后,T1WI上瘤体信号值平均增加32.13(t=-5.156,P<0.01),T2WI上瘤体信号值平均增加了4.73(t=-0.632,P>0.05)。MRI显示42个肿瘤内部无强化,边缘轻度环状强化,肿瘤血供完全阻断,其余6个瘤体内少许强化,再次HIFU治疗后肿瘤内部无强化,肿瘤血供完全阻断。瘤体体积治疗前(50.3±22.7)cm3,经HIFU治疗6个月后为(18.8±12.5)cm3,t检验显示治疗前后肿瘤体积变化差异有统计学意义(P<0.05)。结论 HIFU是治疗子宫肌瘤的一种安全、有效方法,MRI是其疗效评价的一种较好影像方法。  相似文献   

11.
FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…  相似文献   

12.
Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.  相似文献   

13.
In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.  相似文献   

14.
Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.  相似文献   

15.
16.
目的 探讨猪肺磷脂注射液联合经鼻持续气道正压通气(NCPAP)对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性(CK-MB)的影响.方法 选取呼吸衰竭早产儿80例,分为观察组和对照组各40例.对照组采用NCPAP给氧治疗,观察组给予NCPAP给氧联合猪肺磷脂气管内给药.观察两组患儿治疗前及治疗12h、24 h后PaO2、PaCO2、血氧饱和度(SaO2)、pH的变化情况,检测治疗前及治疗5d后血清CK-MB水平;评估两组患儿的临床治疗效果.结果 两组患儿PaO2、PaCO2、SaO2、pH比较,差异均有统计学意义(P<0.05),其中观察组治疗后的PaO2、SaO2、pH均高于对照组,PaCO2则低于对照组.两组的PaO2、SaO2、pH均随观察时间延长而升高(P<0.05),PaCO2均随观察时间的延长而降低(P<0.05).观察组治疗有效率为87.5%,显著高于对照组的70.0% (P <0.05).治疗5d后两组患儿血清CK-MB水平均较前降低(P<0.05),且观察组明显低于对照组(P<0.05).结论 猪肺磷脂注射液气管内给药联合NCPAP可以显著降低呼吸衰竭早产儿CK-MB的含量,提高治疗有效率,起到很好的呼吸循环支持作用.  相似文献   

17.
Evidence obtained from randomized controlled trials (RCTs) has been generally accepted as the gold standard in the evaluation of clinical effectiveness. Readers need to understand the trial design, implementation, results, analysis and interpretation, so as to fully Jnderstand the results of RCTs. Thus, the investigators of RCTs have to report these items in a complete, accurate and clear manner. Since 1998, we have conducted several evaluations on the reporting quality of RCTs published in Chinese journals on traditional Chinese medicine (TCM) and results have shown that there is an urgent need for higher quality RCTs on TCM.  相似文献   

18.
Ankylosing spondylitis is a chronic and progressive disorder with inflammation mainly involving the central axis joints. It mainly affects the cervical spine and the lumbosacral area, with the pathogenesis closely related to the kidney and the Governor Vessel (GV). TCM holds that the syndrome is deficiency in origin and excess in superficiality, which is due to insufficiency of the kidney, deficiency of GV, and blocking of the channels with the invasion of exogenous evil, leading to poor circulation of qi and blood and malnutrition of the bones, muscles and joints. The TCM method of tonifying the kidney and strengthening GV to regulate circulation of qi and blood and check the arthralgia pain should be adopted, with the Kidney-Tonifying and GV Strengthening Decoction (益肾强督汤) prescribed.  相似文献   

19.
20.
CHEMOTHERAPY playsa greatrolein the treat- ment of malignanttumors,especiallyingynecolo- gicalones.But inanticancerchemotherapy,leuko-cytopeniaisfrequentlytheprimarydose-limitingsideeffect factor.Moreover,cancersarefrequentlychemoresistantbe-causeof overexpressionof P-glycoprotein(P-gp), which isencodedby multidrugresistancegene (MDR1 ) and detectableinup to50% ofhuman cancersand renderscellsresistancetoanticancerdrugs.The safetyand potentialtherapeuticbenefitof mdr1 gene transferredto h…  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号